Is Axitinib an imported drug? What are its import channels and domestic sales price?

Axitinib (Axitinib) is an oral small molecule vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitor, mainly used for targeted therapy of advanced renal cell carcinoma. This drug was originally developed and produced by an American original drug company, so it is an imported drug. With its highly selective inhibition of VEGFR 1, 2, and 3, axitinib can effectively inhibit tumor angiogenesis and delay tumor progression in clinical practice.

Axitinib is currently on the market in China and is included in the medical insurance catalog. Patients can purchase it through regular domestic hospital pharmacies. As an imported original drug, its domestic price is relatively high, about more than 4,000 yuan per box. For specific prices and medical insurance reimbursement, please consult the local hospital pharmacy. The inclusion of medical insurance provides patients with certain financial support, allowing more patients who meet the indications to obtain treatment opportunities.

In overseas markets, generic drugs of axitinib are mainly distributed in countries such as India and Laos. The price is significantly lower than that of the original drug, only a few hundred yuan per box. Although the price is low, the pharmaceutical ingredients of these generic drugs are basically the same as the original drugs, and they can be used as a reference purchase option for some patients with greater financial pressure. However, when patients choose to purchase from overseas channels, they should ensure that the source of drugs is formal to avoid quality risks.

While using axitinib, patients should strictly follow the doctor's prescription and not change the dosage or stop the drug at will. During long-term use, blood pressure, liver and kidney function and imaging indicators should be reviewed regularly to detect and deal with adverse reactions in a timely manner. In addition, for patients with greater financial pressure, drugs can be selected based on domestic medical insurance policies and legal overseas channels, so as to achieve an affordable treatment plan while ensuring efficacy.

Reference materials:https://www.drugs.com/